Liraglutide 3 mg (Saxenda, FDA-approved for weight management), an earlier-generation daily GLP-1 injection, demonstrates similar gastrointestinal side effect patterns with diarrhea reported in approximately 21% of patients according to its FDA label
When weight loss occurs on a GLP-1 RA, a homeostatic counter-regulatory response is engaged: resting energy expenditure falls beyond what body composition changes alone would predict (adaptive thermogenesis), ghrelin rises, leptin signaling attenuates, and the defended body weight set point reasserts itself
T., & Pastuszak, A
Arch Neurol 69(7):887893 Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X (2019) The emerging roles of ferroptosis in Huntingtons disease
None of the three components is approved by the FDA or EMA
The integrated stress response